Profile: Jazz Pharmaceuticals PLC (JAZZ.OQ)
Jazz Pharmaceuticals plc, incorporated on March 15, 2005, is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The Company’s marketed products include Xyrem (sodium oxybate oral solution), for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, a treatment for patients with acute lymphoblastic leukemia; Prialt (ziconotide) intrathecal infusion, the only non-opioid intrathecal analgesic indicated for the management of severe chronic pain, and FazaClo (clozapine, USP) HD and FazaClo LD, orally disintegrating clozapine tablets indicated for treatment-resistant schizophrenia, and Versacloz.
Xyrem (sodium oxybate) oral solution
Xyrem is the treatment for both Ehlers-Danlos syndrome (EDS) and cataplexy in patients with narcolepsy. Sodium oxybate, the active pharmaceutical ingredient in Xyrem, is a formulation of the sodium salt of gamma-hydroxybutyrate, an endogenous neurotransmitter and metabolite of gamma-aminobutyric acid. Xyrem was approved for the treatment of cataplexy in patients with narcolepsy.
Erwinaze (asparaginase Erwinia chrysanthemi
Erwinaze, a biologic product, is used in conjunction with chemotherapy to treat patients with ALL who have developed hypersensitivity to E. coli-derived asparaginase. Erwinaze is an asparaginase, a type of enzyme that can deprive leukemic cells of an amino acid essential for their growth. It is derived from a rare bacterium (Erwinia chrysanthemi) and is immunologically distinct from E. coli-derived asparaginase and suitable for patients with hypersensitivity to E. coli-derived treatments.
Defibrotide, the active pharmaceutical ingredient in Defitelio, is the sodium salt of a complex mixture of single-stranded oligodeoxyribonucleotides derived from porcine DNA. Defibrotide has shown a number of pharmacological effects that suggest it has a role in both protection of the endothelial cells that form the inner lining of blood vessels and the restoration of the balance between clot formation and breakdown in the blood.
Prialt (ziconotide) intrathecal infusion
Prialt is an intrathecally administered infusion of ziconotide. It is used for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine. Ziconotide is a synthetic neuroactive peptide known as conotoxin and is the synthetic equivalent of a naturally-occurring conopeptide found in the piscivorous marine snail, Conus Magus.
JZP-110 is a compound in clinical development for the treatment of EDS in patients with narcolepsy. The product is in the Phase III clinical trials in the treatment of EDS in patients with narcolepsy, as well as EDS in patients with obstructive sleep apnoea (OSA).
The Company is conducting pre-clinical research and development work on JZP-386, a deuterium-modified analog of sodium oxybate, the active pharmaceutical ingredient in Xyrem.
The Company competes with Endo Health Solutions Inc., Forest Laboratories, Inc., Shire Pharmaceuticals, Inc., Teva and Valeant.
Jazz Pharmaceuticals PLC
1 Burlington Road
Connaught House, 4th Floor